Evidence map›Paper›PMID 42279407›Full record

ArticleCancers2026

IDH1-Associated m6A Methylation Is Linked to Transcriptomic Heterogeneity in Glioma.

Syeda Maheen Batool, Hanna Lee, Koushik Muralidharan, Saad Murtaza Khan, Ana K Escobedo, Denalda Gashi, Kesli Faber, Nina R Barretts, Emil Ekanayake, Tiffaney Hsia and 9 more

Abstract read
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Syeda Maheen BatoolDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Hanna LeeDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Koushik MuralidharanDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0001-5651-5335
Saad Murtaza KhanDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-1385-2056
Ana K EscobedoDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0001-7816-6068
Denalda GashiDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Kesli FaberDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Nina R BarrettsDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.ORCID 0009-0008-0583-8212
Emil EkanayakeDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Tiffaney HsiaDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Yana Al-InayaDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0003-1881-2376
Aishwarya KosgiDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Julie J MillerTranslational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-1288-593X
Daniel P CahillDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0003-2552-6546
Gavin P DunnDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Bryan D ChoiDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-5090-2470
Allegra A PettiDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Bob S CarterDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Leonora BalajDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0003-0931-9715

Funding

NCI NIH HHS CA237500NCI NIH HHS CA239078NCI NIH HHS CA291826
6 · The paper itself

Abstract

Characterizing the m6A epigenetic landscape is essential for understanding glioma biology, yet transcriptome-wide mapping of these modifications at isoform resolution across specific tumor subtypes has remained limited. Conventional short-read approaches lack the capacity to resolve full-length transcript isoforms or assign m6A modifications to individual transcripts, representing a critical gap in glioma where alternative splicing is pervasive.

methodsWe performed direct RNA nanopore sequencing and transcriptome-wide m6A analysis in 14 glioma tumor tissues, including IDH1-mutant astrocytoma, oligodendroglioma, and IDH1 wild-type glioblastoma, enabling isoform-resolved profiling not accessible by conventional short-read approaches. m6A sites were predicted computationally using the m6Anet deep learning framework, which has been independently benchmarked against MeRIP-seq-derived sites, and high-confidence calls were defined at a probability threshold of ≥0.9 and required detection across multiple patients within each subtype.

resultsIDH1-mutant gliomas showed a higher overall burden of computationally inferred m6A-modified sites, transcripts, and genes than IDH1 wild-type glioblastoma, along with variation in transcript biotypes, regional distribution of m6A sites, and extent of isoform methylation. Differential methylation analysis identified subtype-specific patterns of m6A localization, many of which were observed without corresponding changes in gene-level expression, indicating that m6A variation represents a post-transcriptional regulatory layer not captured by gene-level analysis alone. Integration of gene expression, isoform usage, and m6A status further identified variation in isoform composition and transcript features between astrocytoma and glioblastoma. Analysis of m6A regulators showed subtype-associated expression patterns among readers, writers, and erasers, and exploratory analyses identified isoform-level associations with survival that were not apparent at the gene level.

conclusionsOverall, these data describe subtype-specific patterns of m6A marking and isoform architecture across glioma tissues, derived from computational inference using direct RNA sequencing in a modestly sized cohort and warrant validation by orthogonal methods in larger studies. These findings are consistent with concurrent independent evidence that isoform-specific m6A deposition is evolutionarily conserved across mammals and that long-read isoform resolution reveals transcript diversity in glioma not captured by gene-level analysis. While cohort size and the absence of orthogonal site-level validation suggest that the data require cautious interpretation, this work provides a hypothesis-generating resource and methodological framework for future mechanistic and translational investigation of the glioma epitranscriptome.

Indexed as

epitranscriptomicsgliomaIDH1isoformsN6-methyladenosinenanopore sequencing

Identifiers

PMID42279407
PMCPMC13256496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.